Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectrum Hopes For Synergies With Allos Acquisition Amid Phase III Setback

This article was originally published in The Pink Sheet Daily

Executive Summary

Spectrum issued a tender offer of $1.82 per share for Allos Therapeutics on the same day that it announced the Phase III failure of its bladder cancer drug.

Advertisement

Related Content

Spectrum Failed To Heed FDA Advice On Apaziquone, And Is Paying The Price
Spectrum's Apaziquone: Can Two Failed Studies Lead To An Approval?
Spectrum Puts Its Eggs In One Basket: Folotyn, Beleodaq To Share Confirmatory Trial
AstraZeneca/BMS's Dapagliflozin Needs European Epidemiological Study, But Headed For Strong Label
Shareholder Revolt at AMAG Squelches All-Stock Merger with Equally Struggling Allos
Cancer Drug Zevalin May Finally Thrive Under Spectrum

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073983

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel